Welcome to My Research!
You may have access to the free features available through My Research. You can save searches, save documents, create alerts and more. Please log in through your library or institution to check if you have access.
Translate this article into 20 different languages!
If you log in through your library or institution you might have access to this article in multiple languages.
Get access to 20+ different citations styles
Styles include MLA, APA, Chicago and many more. This feature may be available for free if you log in through your library or institution.
Looking for a PDF of this document?
You may have access to it for free by logging in through your library or institution.
Want to save this document?
You may have access to different export options including Google Drive and Microsoft OneDrive and citation management tools like RefWorks and EasyBib. Try logging in through your library or institution to get access to these tools.
- Preview Available
- Scholarly Journal
L3 Update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients
We're sorry, there is no preview available.
Try and log in through your library or institution to see if they have access.
